Literature DB >> 9431920

Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis.

M Soto1, J M Requena, L Quijada, C Alonso.   

Abstract

In this work, we describe the assembly of a synthetic gene coding for several antigenic determinants found in different Leishmania infantum antigens. Selected epitopes were derived from the ribosomal proteins LiP2a, LiP2b, and LiP0 and from the histone H2A. The resulting gene was overexpressed in Escherichia coli either as a fusion protein (with the vector pMAL-c2) or alone (with the vector pQE). In both cases, high-level bacterial production of the recombinant protein was achieved and the products were found to be stable. Enzyme-linked immunosorbent assay (ELISA) and Western blotting experiments confirmed that the corresponding epitopes are present in the engineered protein. Finally, a serological evaluation of this multiple-epitope protein by Falcon assay screening test-ELISA revealed a sensitivity of 79 to 93% and a specificity of 96 to 100% in diagnosis of canine visceral leishmaniasis, indicating that this protein represents a valuable tool for serodiagnosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9431920      PMCID: PMC124807     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/M-2 of Leishmania amazonensis.

Authors:  K L Lohman; P J Langer; D McMahon-Pratt
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Two syntopic zymodemes of Leishmania infantum cause human and canine visceral leishmaniasis in the Naples area, Italy.

Authors:  M Gramiccia; L Gradoni; L di Martino; R Romano; D Ercolini
Journal:  Acta Trop       Date:  1992-04       Impact factor: 3.112

3.  Epidemiology, diagnosis and control of leishmaniasis in the Mediterranean region.

Authors:  Y Ozbel; N Turgay; S Ozensoy; A Ozbilgin; M Z Alkan; M A Ozcel; C L Jaffe; L Schnur; L Oskam; P Abranches
Journal:  Ann Trop Med Parasitol       Date:  1995-12

4.  Molecular characterization of a Leishmania donovani infantum antigen identified as histone H2A.

Authors:  M Soto; J M Requena; L C Gomez; I Navarrete; C Alonso
Journal:  Eur J Biochem       Date:  1992-04-01

5.  An experimental model for canine visceral leishmaniasis.

Authors:  P Abranches; G Santos-Gomes; N Rachamim; L Campino; L F Schnur; C L Jaffe
Journal:  Parasite Immunol       Date:  1991-09       Impact factor: 2.280

6.  Recombinant Leishmania Hsp90 and Hsp70 are recognized by sera from visceral leishmaniasis patients but not Chagas' disease patients.

Authors:  C R de Andrade; L V Kirchhoff; J E Donelson; K Otsu
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

7.  Demonstration of Leishmania specific cell mediated and humoral immunity in asymptomatic dogs.

Authors:  M Cabral; J O'Grady; J Alexander
Journal:  Parasite Immunol       Date:  1992-09       Impact factor: 2.280

8.  Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis.

Authors:  J M Burns; W G Shreffler; D R Benson; H W Ghalib; R Badaro; S G Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

9.  Antibody responses of visceral leishmaniasis patients to gp63, a major surface glycoprotein of Leishmania species.

Authors:  W G Shreffler; J M Burns; R Badaró; H W Ghalib; L L Button; W R McMaster; S G Reed
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

10.  Leishmanin reaction in the human population of a highly endemic focus of canine leishmaniasis in Alpes-Maritimes, France.

Authors:  P Marty; Y Le Fichoux; D Giordana; A Brugnetti
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 May-Jun       Impact factor: 2.184

View more
  27 in total

Review 1.  Diagnosis of visceral leishmaniasis: developments over the last decade.

Authors:  Gurumurthy Srividya; Arpita Kulshrestha; Ruchi Singh; Poonam Salotra
Journal:  Parasitol Res       Date:  2011-11-09       Impact factor: 2.289

2.  Recombinant leishmania antigens for serodiagnosis of visceral leishmaniasis.

Authors:  S Passos; L P Carvalho; G Orge; S M Jerônimo; G Bezerra; M Soto; C Alonso; E M Carvalho
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

Review 3.  A new Leishmania-specific hypothetical protein and its non-described specific B cell conformational epitope applied in the serodiagnosis of canine visceral leishmaniasis.

Authors:  Daniela P Lage; Vívian T Martins; Mariana C Duarte; Lourena E Costa; Esther Garde; Laura M Dimer; Amanda C S Kursancew; Miguel A Chávez-Fumagalli; Danielle F de Magalhães-Soares; Daniel Menezes-Souza; Bruno M Roatt; Ricardo A Machado-de-Ávila; Manuel Soto; Carlos A P Tavares; Eduardo A F Coelho
Journal:  Parasitol Res       Date:  2016-01-19       Impact factor: 2.289

4.  Subtractive phage display selection from canine visceral leishmaniasis identifies novel epitopes that mimic Leishmania infantum antigens with potential serodiagnosis applications.

Authors:  Lourena E Costa; Mayara I S Lima; Miguel A Chávez-Fumagalli; Daniel Menezes-Souza; Vivian T Martins; Mariana C Duarte; Paula S Lage; Eliane G P Lopes; Daniela P Lage; Tatiana G Ribeiro; Pedro H R Andrade; Danielle F de Magalhães-Soares; Manuel Soto; Carlos A P Tavares; Luiz R Goulart; Eduardo A F Coelho
Journal:  Clin Vaccine Immunol       Date:  2013-11-20

5.  Epidemiological implications of the use of various methods for the diagnosis of canine leishmaniasis in dogs with different characteristics and in differing prevalence scenarios.

Authors:  Manuel Morales-Yuste; Francisco Morillas-Márquez; Victoriano Díaz-Sáez; Sergio Barón-López; Carmen Acedo-Sánchez; Joaquina Martín-Sánchez
Journal:  Parasitol Res       Date:  2012-01-10       Impact factor: 2.289

6.  Specific serodiagnosis of canine visceral leishmaniasis using Leishmania species ribosomal protein extracts.

Authors:  Eduardo A F Coelho; Laura Ramírez; Mariana A F Costa; Vinicio T S Coelho; Vivian T Martins; Miguel A Chávez-Fumagalli; Dulcilene M Oliveira; Carlos A P Tavares; Pedro Bonay; Carlos Gómez Nieto; Daniel R Abánades; Carlos Alonso; Manuel Soto
Journal:  Clin Vaccine Immunol       Date:  2009-10-07

7.  Sensitive and specific serodiagnosis of Leishmania infantum infection in dogs by using peptides selected from hypothetical proteins identified by an immunoproteomic approach.

Authors:  Miguel A Chávez-Fumagalli; Vivian T Martins; Miriam C S Testasicca; Daniela P Lage; Lourena E Costa; Paula S Lage; Mariana C Duarte; Henrique G Ker; Tatiana G Ribeiro; Fernando A A Carvalho; Wiliam C B Régis; Alexandre B Dos Reis; Carlos A P Tavares; Manuel Soto; Ana Paula Fernandes; Eduardo A F Coelho
Journal:  Clin Vaccine Immunol       Date:  2013-04-03

8.  Leishmania major infection in susceptible and resistant mice elicit a differential humoral response against a total soluble fraction and defined recombinant antigens of the parasite.

Authors:  Virginia Iniesta; Inés Corraliza; Jesualdo Carcelén; Luis Gómez Gordo; Javier Fernández-Cotrina; Juan Carlos Parejo; Javier Carrión; Manuel Soto; Carlos Alonso; Carlos Gómez Nieto
Journal:  Parasitol Res       Date:  2008-01-10       Impact factor: 2.289

9.  The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers.

Authors:  S Iborra; D R Abánades; N Parody; J Carrión; R M Risueño; M A Pineda; P Bonay; C Alonso; M Soto
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

10.  Key role of the 3' untranslated region in the cell cycle regulated expression of the Leishmania infantum histone H2A genes: minor synergistic effect of the 5' untranslated region.

Authors:  Daniel R Abanades; Laura Ramírez; Salvador Iborra; Ketty Soteriadou; Victor M González; Pedro Bonay; Carlos Alonso; Manuel Soto
Journal:  BMC Mol Biol       Date:  2009-05-21       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.